Skip to main content
Figure 6 | EJNMMI Research

Figure 6

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues

Figure 6

Therapeutic effect of the177 Lu-labelled BN analogues. Peptides were labelled with high specific activity (2 × 20 MBq/0.3 nmol peptide each) and injected in mice with PC-3 tumour xenografts. The graph shows the comparison of treatment with the PEGylated (group D) and the non-PEGylated (group F) 177Lu-labelled BN analogues. Besides, it shows the influence of timing the second dose (second dose at day 7 vs. day 14; group E vs. group D). Data are expressed as the volume of tumour relative to the volume in the same animal immediately before the first injection (mean ± SD of six animals).

Back to article page